Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.66 USD | +3.84% | +6.03% | +38.70% |
May. 09 | Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M | MT |
May. 09 | XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+38.70% | 288M | C- | ||
+8.29% | 113B | B+ | ||
+10.21% | 106B | B+ | ||
+0.41% | 22.27B | B | ||
-11.90% | 22.22B | B+ | ||
-5.99% | 19.43B | A- | ||
-37.36% | 17.87B | A- | ||
-5.17% | 17.24B | B | ||
+7.70% | 14.29B | C+ | ||
+37.65% | 12.52B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- XOMA Stock
- Ratings XOMA Corporation